Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2017
OPERATING ACTIVITIES
Net income	$ 330	$ 5,199	$ 9,641
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,632	22,801	21,704
Deferred income taxes	285	6,174	(2,329)
Provision for doubtful accounts receivable	2,028	2,199	686
Stock-based compensation	2,236	3,581	3,740
Other	(1,765)	7	(679)
Change in assets and liabilities:
Trade accounts receivable	7,594	(6,668)	(17,972)
Prepaid expenses, other current assets, and other assets	4,119	(18,889)	(4,856)
Trade accounts payable, accrued expenses, other current liabilities, and other liabilities	(7,546)	12,769	16,722
Customer deposits at IDT Financial Services Limited, our Gibraltar-based bank	59,077	14,660	18,980
Deferred revenue	(3,853)	(21,439)	(9,543)
Net cash provided by operating activities	85,137	20,394	36,094
INVESTING ACTIVITIES
Capital expenditures	(18,681)	(20,567)	(22,949)
Proceeds from sale of interest in Straight Path IP Group Holding, Inc.		6,000
Purchase of IP interest from Straight Path Communications Inc.		(6,000)
Payments for acquisitions, net of cash acquired	(5,526)		(1,827)
Cash used for purchase of investments	(1,000)	(53)	(9,438)
Proceeds from redemptions of investments	1,000		15
Purchases of marketable securities	(7,276)	(22,523)	(53,402)
Proceeds from maturities and sales of marketable securities	5,312	41,502	47,996
Net cash used in investing activities	(26,171)	(1,641)	(39,605)
FINANCING ACTIVITIES
Dividends paid		(13,941)	(17,874)
Distributions to noncontrolling interests	(1,520)	(1,040)	(1,482)
Repayment of other liabilities acquired	(654)
Proceeds from sales of Class B common stock to Howard S. Jonas	13,272		24,930
Proceeds from sale of interest and rights in Rafael Pharmaceuticals, Inc. to Howard S. Jonas			1,000
Proceeds from sale of member interests in CS Pharma Holdings, LLC			1,250
Cash of Rafael deconsolidated as a result of spin-off		(9,287)
Proceeds from exercise of stock options			836
Proceeds from borrowings under revolving credit facility	3,000	22,320
Repayments of borrowings under revolving credit facility	(3,000)	(22,320)
Repurchases of Class B common stock	(3,882)	(2,293)	(1,838)
Net cash provided by (used in) financing activities	7,216	(26,561)	6,822
Effect of exchange rate changes on cash, cash equivalents, and restricted cash and cash equivalents	(12,180)	(957)	293
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents	54,002	(8,765)	3,604
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of year	203,197	211,962	208,358
Cash, cash equivalents, and restricted cash and cash equivalents at end of year	257,199	203,197	211,962
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash payments made for interest	186	94	288
Cash payments made for income taxes	46	192	576
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES
Howard S. Jonas's advance payment used for sale of Class B common stock	1,500
Net assets excluding cash and cash equivalents of Rafael deconsolidated as a result of spin-off		(105,632)
Reclassification of liability for member interests in CS Pharma Holdings, LLC			$ 8,750